Buy & Sell Sony Group Corp (SONY) – Sony Group Corp Price Today
Aura AI Summary
Key Stats
- $132.15BMarket Cap
- TechnologySector
- -14.83%3M Drawdown
- $128.57BEnterprise Value
- 0.71%Dividend Yield
- 88% Buy | 12% SellTrading Activity
- 85 daysTypical Hold Time
Sony Group Corp (SONY) is currently valued at a market capitalization of $132.15B, with an enterprise value of $128.57B. Over the past 52 weeks, Sony Group Corp has traded between a low of $19.64 and a high of $30.26, highlighting its annual price range. Over the past three months, Sony Group Corp has recorded a drawdown of -14.83%, reflecting recent price volatility. Sony Group Corp offers a dividend yield of 0.71%, with the most recent dividend of $0.07 paid on 31 Mar 25. On average, investors hold Sony Group Corp for approximately 85 days, indicating typical investor behavior on the platform.
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Most Recent News
CN Energy's Pathenbot launches intelligent robotic cargo sorting in the US with a 100,000-unit order.
CN Energy Group's subsidiary Pathenbot has signed an order to provide intelligent robotic cargo sorting services in the United States, marking the commercial launch of these services. The initial order covers 100,000 units and includes barcode scanni...
BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting
BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonst...
BioNTech reveals promising late-stage cancer drug data at ASCO 2026, advancing treatments for lung and ovarian cancers.
BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell ...